IRIS UniCatt

Salutari, Vanda
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.188
AS - Asia 2.178
EU - Europa 1.567
SA - Sud America 380
AF - Africa 60
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.382
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.131
SG - Singapore 859
CN - Cina 668
DE - Germania 414
BR - Brasile 309
IT - Italia 273
VN - Vietnam 217
SE - Svezia 209
FR - Francia 163
IN - India 100
IE - Irlanda 92
GB - Regno Unito 77
UA - Ucraina 73
PL - Polonia 64
ID - Indonesia 61
RU - Federazione Russa 53
JP - Giappone 52
HK - Hong Kong 49
FI - Finlandia 48
AR - Argentina 33
BD - Bangladesh 30
CA - Canada 26
IQ - Iraq 24
TR - Turchia 24
KR - Corea 23
ZA - Sudafrica 22
NL - Olanda 21
MX - Messico 18
AT - Austria 15
PK - Pakistan 14
BE - Belgio 12
SA - Arabia Saudita 9
CH - Svizzera 8
PY - Paraguay 8
CO - Colombia 7
EC - Ecuador 7
LT - Lituania 7
MA - Marocco 7
VE - Venezuela 7
CI - Costa d'Avorio 6
CZ - Repubblica Ceca 6
KE - Kenya 6
KZ - Kazakistan 6
AU - Australia 5
CL - Cile 5
AL - Albania 4
DZ - Algeria 4
ES - Italia 4
IR - Iran 4
JO - Giordania 4
RO - Romania 4
TN - Tunisia 4
AZ - Azerbaigian 3
EG - Egitto 3
GE - Georgia 3
IL - Israele 3
OM - Oman 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
AW - Aruba 2
BG - Bulgaria 2
CR - Costa Rica 2
ET - Etiopia 2
GA - Gabon 2
HU - Ungheria 2
JM - Giamaica 2
KG - Kirghizistan 2
LB - Libano 2
LV - Lettonia 2
MK - Macedonia 2
MY - Malesia 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
PE - Perù 2
PH - Filippine 2
PS - Palestinian Territory 2
SN - Senegal 2
TJ - Tagikistan 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
AO - Angola 1
BS - Bahamas 1
BZ - Belize 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GR - Grecia 1
GT - Guatemala 1
IM - Isola di Man 1
IS - Islanda 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MD - Moldavia 1
MT - Malta 1
NG - Nigeria 1
NP - Nepal 1
PA - Panama 1
PT - Portogallo 1
Totale 6.379
Salva come PNG Salva come JPEG
Città #
Singapore 453
Chandler 249
San Jose 246
Ashburn 231
Hangzhou 185
Beijing 134
Dublin 92
Ho Chi Minh City 71
New York 69
Los Angeles 59
Hefei 58
Hyderabad 56
Warsaw 55
San Mateo 54
Hanoi 53
Jakarta 53
Lauterbourg 52
Rome 50
Wilmington 48
Ann Arbor 46
Tokyo 45
Frankfurt am Main 43
Hong Kong 43
Jacksonville 43
Munich 38
Dallas 37
Redmond 33
Milan 31
Nanjing 31
Boston 30
Moscow 29
The Dalles 29
Houston 26
São Paulo 26
Bremen 25
Dearborn 24
Cattolica 23
Helsinki 22
Princeton 21
Council Bluffs 20
Nürnberg 20
Fairfield 19
Kent 19
Seoul 18
Johannesburg 17
Santa Clara 17
St Louis 17
Redwood City 16
Seattle 16
Buffalo 15
Atlanta 14
Chicago 14
Naples 14
Orem 14
Marseille 13
Nanchang 13
Woodbridge 13
Izmir 12
Lawrence 12
Paris 12
Shenyang 12
Brooklyn 11
Brussels 10
Chennai 10
Dhaka 10
Haiphong 10
London 10
Phoenix 10
Denver 9
Düsseldorf 9
Rio de Janeiro 9
Shanghai 9
Vienna 9
Washington 9
Boardman 8
Cambridge 8
Da Nang 8
Jiaxing 8
Amsterdam 7
Guangzhou 7
Kunming 7
Manchester 7
Mountain View 7
Stockholm 7
University Park 7
Zhengzhou 7
Abidjan 6
Baghdad 6
Bologna 6
Brasília 6
Campinas 6
Detroit 6
Falkenstein 6
Mexico City 6
Montreal 6
Nairobi 6
Portsmouth 6
Roubaix 6
Turku 6
Albano Laziale 5
Totale 3.546
Salva come PNG Salva come JPEG
Nome #
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer 521
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial 360
Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence 314
Paclitaxel, epirubicin, and cisplatin (TEP) regimen as neoadjuvant treatment in locally advanced cervical cancer: long-term results 233
Early detection of recurrence or progression disease in patients with ovarian cancer after primary debulking surgery: a diagnostic challenge still unresolved. Correlation between CT findings and CA 125 levels. 202
A preliminary Quality Control (QC) for next generation sequencing (NGS) library evaluation turns out to be a very useful tool for a rapid detection of BRCA1/2 deleterious mutations 188
Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer. 184
Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: A case-control study 154
The 'lead vessel': a vascular ultrasound feature of metastasis in the ovaries. 146
Concomitant boost dose escalation plus large-field preoperative chemoradiation in locally advanced carcinoma of the uterine cervix: results of a phase I study (LARA-CC-1). 139
Stereotactic radiotherapy in recurrent gynecological cancer: a case series 137
"Occult" ovarian Leydig cell tumor: when laboratory tells more than imaging 137
Successful multimodal treatment of a breast cancer patient with a recurrence invading the chest wall 134
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study 133
Optimizing treatment in recurrent epithelial ovarian cancer 128
Recent progress in the use of pharmacotherapy for endometrial cancer 117
PARP Inhibitors Resistance: Mechanisms and Perspectives 115
Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer 115
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial 113
Successful multimodal treatment of a breast cancer patient with a recurrence invading the chest wall 113
Medi-Cinema: A Pilot Study on Cinematherapy and Cancer as A New Psychological Approach on 30 Gynecological Oncological Patients 112
Advanced and recurrent endometrial cancer: State of the art and future perspectives 110
Real-world outcomes of PARP inhibitor maintenance in advanced ovarian cancer: a focus on disease patterns and treatment modalities at recurrence 109
Immunotherapy-related imaging findings in patients with gynecological malignancies: What radiologists need to know 109
New medical approaches in advanced ovarian cancer 107
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial 106
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials 106
Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon? 105
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis 103
Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) Applied to Platinum-Resistant Recurrence of Ovarian Tumor: A Single-Institution Experience (ID: PARROT Trial) 100
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 97
Medi-Cinema: A Pilot Study on Cinematherapy and Cancer as A New Psychological Approach on 30 Gynecological Oncological Patients 96
Controversy in treatment of advanced ovarian cancer 96
Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: The MITO-8,MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study 95
Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study 95
A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer 94
Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study 94
A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer 93
Newly diagnosed ovarian cancer: Which first-line treatment? 92
Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives 89
Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinumbased chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer 86
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: A retrospective MITO group study 86
Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome 82
Combining targeted therapies in ovarian cancer 80
Radical Surgery in Advanced Cervical Cancer Patients Receiving Bevacizumab-Containing Chemotherapy: A "Real Life Experience" 79
Neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: A phase II, open label multicenter study (NUVOLA trial) 78
A retrospective analysis of trabectedin infusion by peripherally inserted central venous catheters: A multicentric Italian experience 77
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 77
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 75
New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphere 75
Genome tumor profiling in endometrial cancer and clinical relevance in endometrial cancer management: A retrospective single-center experience 72
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel 70
Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26) 64
Stereotactic Body Radiation Therapy for Oligoprogressive Ovarian Cancer Patients Treated During Poly(ADP-Ribose)-Polymerase Inhibitor Maintenance: Efficacy and Adverse Events From the Epimetheo Retrospective Study 44
Management of early-stage ovarian cancer: Open questions and debated issues 42
Treatment of Oligometastatic Parenchymal Lesions in Ovarian Cancer With Stereotactic Ablative Radiation Therapy: A Multicenter Prospective Phase 2 Trial (MITO RT3/RAD) 35
Lifestyle and environmental factors in women carrying BRCA pathogenic variants with and without cancer 35
Stereotactic Ablative Radiation Therapy for Oligometastatic Ovarian Cancer Lymph Node Disease: The MITO-RT3/RAD Phase II Trial 25
Totale 6.873
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.361
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.361
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202176 0 0 0 0 0 0 0 0 0 0 59 17
2021/2022286 39 16 2 15 17 6 3 60 5 13 54 56
2022/2023722 67 98 46 104 58 93 27 50 94 20 41 24
2023/2024511 20 131 29 35 18 82 48 15 4 20 53 56
2024/20251.086 28 17 82 39 71 38 40 46 155 135 235 200
2025/20262.614 343 100 224 349 430 171 403 157 226 204 7 0
Totale 6.873